{"id":6197,"date":"2024-03-22T11:51:06","date_gmt":"2024-03-22T10:51:06","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/?post_type=congress&#038;p=6197"},"modified":"2024-07-01T13:09:25","modified_gmt":"2024-07-01T12:09:25","slug":"eha2024","status":"publish","type":"congress","link":"http:\/\/beonemedaffairs.com\/begenius\/congress\/6197\/eha2024\/","title":{"rendered":"EHA2024"},"content":{"rendered":"","protected":false},"template":"","meta":{"_acf_changed":false,"editor_notices":[]},"specialisation":[],"class_list":["post-6197","congress","type-congress","status-publish","hentry","congress_category-congress"],"acf":{"show_in_cards":false,"show_in_filter":false,"visible_for_guests":true,"show_popup":false,"acronym":"EHA","title":"","sub-heading-override":"","congress_type":"Congress","start_date":"2024-06-12T00:00:00+00:00","end_date":"2024-06-15T00:00:00+00:00","location":"Madrid, Spain","extra_flag":"","deactivated":false,"alternate_button_text":"","tag":19,"content_block":[{"content_block_title":"Were you unable to connect with us at EHA2024 Hybrid Congress?","content_block_text":"If so, please <a href=\"https:\/\/www.beigene.com\/contact-us\/\"><span style=\"text-decoration: underline;\"><strong>contact us here<\/strong><\/span><\/a>. Our team will be pleased to talk to you through our congress activities and answer any queries you may have.","content_block_image":""},{"content_block_title":"Did you miss our BeiGene-sponsored Satellite Symposia?","content_block_text":"If so, slides and webcasts of both symposia are available on our website. See below for details.","content_block_image":""},{"content_block_title":"Satellite Symposium: \u2018The data behind your treatment selection in CLL &amp; indolent lymphomas\u2019","content_block_text":"Chaired by <strong>Prof. Wendtner<\/strong>, this first satellite symposium provided insights into current therapeutic options for patients with treatment-na\u00efve (TN) and relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL). The experts discussed their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton\u2019s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenstr\u00f6m\u2019s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) were also presented. You can download the slides and view the webcast <a href=\"https:\/\/beonemedaffairs.com\/6301\/satellite-symposium-the-data-behind-your-treatment-selection-in-chronic-lymphocytic-leukemia-cll-indolent-lymphomas\/\"><span style=\"text-decoration: underline;\"><strong>here<\/strong><\/span><\/a>.","content_block_image":6380},{"content_block_title":"Satellite Symposium: \u2018All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment\u2019","content_block_text":"In the second satellite symposium, a panel of hematology experts chaired by <strong>Prof. Stilgenbauer, <\/strong>discussed topics such as an introduction to BTKis for CLL in clinical practice, resistance mutations and BTKi switching, the safety profile of BTKis and management of cardiovascular events, and pharmacokinetics and pharmacodynamics of BTKis. The slides and webcast are available <a href=\"https:\/\/beonemedaffairs.com\/6303\/satellite-symposium-all-you-need-to-know-when-managing-chronic-lymphocytic-leukemia-cll-or-indolent-lymphoma-patients-under-brutons-tyrosine-kinase-btki-treatment\/\"><span style=\"text-decoration: underline;\"><strong>here<\/strong><\/span><\/a>.","content_block_image":6382},{"content_block_title":"Product Theater: \u2018Designed to be different: A next-generation Bruton\u2019s tyrosine kinase inhibitor (BTKi) in CLL\u2019","content_block_text":"At this promotional event, <strong>Dr. Scarf\u00f2 <\/strong>presented evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing\/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.\r\n\r\nLearn more about BeiGene <a href=\"https:\/\/beonemedaffairs.com\/\"><span style=\"text-decoration: underline;\"><strong>here<\/strong><\/span><\/a>.","content_block_image":6384},{"content_block_title":" ","content_block_text":"<p style=\"text-align: center;\"><sub><strong>0524-BRU-PRC-178<\/strong><\/sub><\/p>","content_block_image":""}],"ics_file":"http:\/\/beonemedaffairs.com\/begenius\/wp-content\/uploads\/sites\/30\/2024\/03\/EHA2024-1.ics","summary":"European Hematology Association","related":"","field_page_schema_override":null,"field_show_asset_alt":false},"_links":{"self":[{"href":"http:\/\/beonemedaffairs.com\/begenius\/wp-json\/wp\/v2\/congress\/6197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/beonemedaffairs.com\/begenius\/wp-json\/wp\/v2\/congress"}],"about":[{"href":"http:\/\/beonemedaffairs.com\/begenius\/wp-json\/wp\/v2\/types\/congress"}],"acf:term":[{"embeddable":true,"taxonomy":"post-tag","href":"http:\/\/beonemedaffairs.com\/begenius\/wp-json\/wp\/v2\/post-tag\/19"}],"wp:attachment":[{"href":"http:\/\/beonemedaffairs.com\/begenius\/wp-json\/wp\/v2\/media?parent=6197"}],"wp:term":[{"taxonomy":"specialisation","embeddable":true,"href":"http:\/\/beonemedaffairs.com\/begenius\/wp-json\/wp\/v2\/specialisation?post=6197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}